These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1877 related articles for article (PubMed ID: 31474630)

  • 1. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An Overview of NAFLD/NASH in Japan].
    Kim SR; Kim KI
    Yakugaku Zasshi; 2016; 136(4):565-72. PubMed ID: 27040340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
    Roeb E; Geier A
    Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P; Bush H; Younossi ZM
    Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
    J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.